...
首页> 外文期刊>Oncogene >-Trcp and CK1-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma
【24h】

-Trcp and CK1-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma

机译:-TrCP和CK1介导的LZTS2的降解激活PI3K / AKT信号传导,以驱动肝细胞癌的肿瘤发生和转移

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Distant metastasis is the leading cause of treatment failure in patients with hepatocellular carcinoma (HCC). However, the underlying mechanisms have not been fully elucidated. Here, we report that Leucine zipper tumor suppressor 2 (LZTS2) is downregulated and correlated with poor prognosis in HCC. Furthermore, we provide evidence that LZTS2 associates with p85 to inhibit the activation of PI3K/AKT signaling and impairs HCC tumorigenesis and metastasis in vitro and in vivo. Moreover, we identify LZTS2 as a bona fide substrate of the E3 ligase -Trcp and protein kinase CK1, which are responsible for the ubiquitination and degradation of LZTS2. Importantly, we show that the -Trcp and CK1-mediated degradation of LZTS2 promotes HCC progression and metastasis by activating PI3K/AKT signaling. Collectively, our study not only illustrates the roles of LZTS2 in regulating HCC tumorigenesis and metastasis but also reveals a novel posttranslational modification of LZTS2 by -Trcp and CK1, indicating that the -Trcp/CK1/LZTS2/PI3K axis may be a novel oncogenic driver involved in HCC progression and metastasis.
机译:远处转移是肝细胞癌(HCC)患者治疗失败的主要原因。然而,潜在机制尚未完全阐明。在这里,我们报告称亮氨酸拉链肿瘤抑制器2(LZTS2)是下调并与HCC预后差的相关性。此外,我们提供的证据表明,LZTS2与P85相关联抑制PI3K / AKT信号传导的激活,并在体外和体内损害HCC肿瘤瘤瘤和转移。此外,我们将LZTS2鉴定为E3连接酶-TRCP和蛋白激酶CK1的真底底物,其负责LZTS2的泛素化和降解。重要的是,我们表明-TRCP和CK1介导的LZTS2介导的降解通过激活PI3K / AKT信号传导来促进HCC进展和转移。统称,我们的研究不仅说明了LZTS2在调节HCC肿瘤引发和转移方面的作用,还揭示了-TRCP和CK1的新型后期改性,表明-TRCP / CK1 / LZTS2 / PI3K轴可以是新型致癌驾驶员参与HCC进展和转移。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号